Home › Metastatic Cancer › Florida › Miami
Metastatic Cancer clinical trials in Miami, FL
24 studies for Metastatic Cancer are looking for participants at sites in and around Miami (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
RecruitingPhase 3
- Miami Cancer Institute, Miami
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RecruitingPhase 3
- Research Site, Miami
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
RecruitingPhase 2
- Sylvester Comprehensive Cancer Center, Miami
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RecruitingPhase 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RecruitingPhase 3
- University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RecruitingPhase 1/2
- Sylvester Comprehensive Cancer Center - Miami, Miami
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
RecruitingPhase 1
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami
- UM Sylvester Comprehensive Cancer Center at Kendall, Miami
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- Miami Cancer Institute at Baptist Health, Inc., Miami
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
RecruitingPhase 1
- University of Miami, Miami
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
RecruitingPhase 3
- University Of Miami-SCCC-Miami, Miami
- University of Miami_SCCC - Kendall, Miami
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecruitingPhase 3
- Research Site, Miami
- Research Site, Miami
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
RecruitingPhase 1
- Sylvester Comprehensive Cancer Center, Miami
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
RecruitingPhase 3
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
RecruitingPhase 1/2
- University of Miami; Sylvester Cancer Center, Miami
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
RecruitingPhase 2/3
- Sylvester Comprehensive Cancer Center, Miami
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingPhase 2/3
- Sylvester Comprehensive Cancer Center, Miami
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
RecruitingPhase 1
- Sylvester Comprehensive Cancer Center, Miami
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RecruitingPhase 1
- University of Miami - Sylvester Comprehensive Cancer Center, Miami
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
RecruitingPhase 3
- University of Miami, Miami
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecruitingObservational study
- Massive Bio SYNERGY-AI site, Miami
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
RecruitingPhase 3
- Miami Cancer Institute, Miami
A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- University of Miami, Miami
Metastatic Cancer trials in other cities
- Houston, TX104 studies
- New York City, NY93 studies
- Nashville, TN70 studies
- Boston, MA63 studies
- Los Angeles, CA57 studies
- St. Louis, MO54 studies
- Arlington, VA53 studies
- Philadelphia, PA46 studies
- Chicago, IL45 studies
- San Antonio, TX44 studies
- Washington, DC43 studies
- Dallas, TX42 studies
Other studies in Miami
- Breast Cancer42 studies
- Cancer (all types)36 studies
- Non-Small Cell Lung Cancer31 studies
- Prostate Cancer27 studies
- Obesity27 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
- Overweight23 studies
- Multiple Myeloma21 studies
- Ulcerative Colitis21 studies
- Alzheimer's Disease20 studies
- Lung Cancer20 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.